RSS Feeds
Tumor Necrosis Factor-α Inhibitor Therapy in Erosive Polyarthritis Secondary to Systemic Sclerosis
- Silvia Bosello, MD;
- Maria De Santis, MD;
- Barbara Tolusso, BS;
- Angelo Zoli, MD; and
- Gianfranco Ferraccioli, MD
- From the Catholic University of the Sacred Heart, 00168 Rome, Italy.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Inflammatory arthritis can occur in patients with systemic sclerosis. In some cases, the condition is erosive and the patient is rheumatoid factor–seronegative, whereas some patients have rheumatoid arthritis that overlaps with diffuse (1) or limited (2) systemic sclerosis. Symptoms may not respond to corticosteroid or methotrexate therapy.
Objective: To …
This 100-word excerpt has been provided in the absence of an abstract.
